Geoffrey D. Wool

1.8k total citations · 1 hit paper
53 papers, 949 citations indexed

About

Geoffrey D. Wool is a scholar working on Surgery, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Geoffrey D. Wool has authored 53 papers receiving a total of 949 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 23 papers in Hematology and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Geoffrey D. Wool's work include Platelet Disorders and Treatments (12 papers), Blood groups and transfusion (8 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (7 papers). Geoffrey D. Wool is often cited by papers focused on Platelet Disorders and Treatments (12 papers), Blood groups and transfusion (8 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (7 papers). Geoffrey D. Wool collaborates with scholars based in United States, Australia and Austria. Geoffrey D. Wool's co-authors include Jonathan Miller, Godfrey S. Getz, Catherine A. Reardon, Timothy Carll, Anne Deucher, Colin Reardon, Chuanyi M. Lu, Tomáš Vaisar, Brenda Sweeney and Britt‐Marie Ljung and has published in prestigious journals such as JAMA, Blood and PLoS ONE.

In The Last Decade

Geoffrey D. Wool

43 papers receiving 927 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Impact of COVID-19 Disease on Platelets and Coagulation

2020 320 citations Geoffrey D. Wool, Jonathan Miller Pathobiology profile →

Peers

Countries citing papers authored by Geoffrey D. Wool

Since Specialization

Citations

This map shows the geographic impact of Geoffrey D. Wool's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey D. Wool with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey D. Wool more than expected).

Fields of papers citing papers by Geoffrey D. Wool

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey D. Wool. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey D. Wool. The network helps show where Geoffrey D. Wool may publish in the future.

Co-authorship network of co-authors of Geoffrey D. Wool

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey D. Wool. A scholar is included among the top collaborators of Geoffrey D. Wool based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey D. Wool. Geoffrey D. Wool is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clonal Persistence of Anti-PF4 Antibodies in VITT Represents an MGTS-like State 2024 ·Blood ·Adam J. Kanack, (unknown), (unknown), (unknown), Geoffrey D. Wool, (unknown), Mouhamed Yazan Abou‐Ismail, Kristi J. Smock, David L. Green, Krishna Gundabolu, (unknown), Mindy Kohlhagen, David Murray, (unknown)	0
2	Ratios of calcium to citrate administration in blood transfusion for traumatic hemorrhage: A retrospective cohort study 2024 ·Transfusion ·(unknown), (unknown), Atul Gupta, Chuanhong Liao, Geoffrey D. Wool, (unknown), Timothy Carll	0
3	Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study 2024 ·American Journal of Clinical Pathology ·Genevieve M. Crane, Julia T. Geyer, Beenu Thakral, Sa A. Wang, Geoffrey D. Wool, (unknown), Adam R. Davis, Leonardo Boiocchi, David Bosler, Carlos E. Bueso‐Ramos, Daniel A. Arber, Tracy I. George, Adam Bagg, Robert P. Hasserjian, Attilio Orazi, Eric D. Hsi, Heesun J. Rogers	0
4	Sensitivity and specificity of thromboelastography for hyperfibrinolysis: Comparison of TEG 5000 and TEG 6S CK LY30 systems 2023 ·American Journal of Clinical Pathology ·(unknown), Timothy Carll, (unknown), Geoffrey D. Wool	1
5	Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic? 2023 ·Blood Advances ·Amrita Sarkar, Sanjay Khandelwal, (unknown), Hyun‐Jun Kim, Yves Gruel, Jérôme Rollin, Freda Passam, Geoffrey D. Wool, Gowthami M. Arepally, Douglas B. Cines, Lubica Rauova, Mortimer Poncz	6
6	Viscoelastic testing: Critical appraisal of new methodologies and current literature 2023 ·International Journal of Laboratory Hematology ·Geoffrey D. Wool, Timothy Carll	9
7	Hyperhemolysis in a patient with sickle cell disease and recent SARS‐CoV‐2 infection, with complex auto‐ and alloantibody work‐up, successfully treated with tocilizumab 2022 ·Transfusion ·(unknown), (unknown), Timothy Carll, Savita Singh, Paul Mansfield, Geoffrey D. Wool	9
8	Assessment of histological characteristics, imaging markers, and rt-PA susceptibility of ex vivo venous thrombi 2021 ·Scientific Reports ·(unknown), Alexey Dimov, (unknown), (unknown), (unknown), Rana O. Afifi, Geoffrey D. Wool, Yuanyuan Zha, Steffen Sammet, Zheng Feng Lu, Osman Ahmed, Jonathan Paul, Kenneth B. Bader	16
9	Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban 2021 ·Archives of Pathology & Laboratory Medicine ·Oksana Volod, Marian A. Rollins‐Raval, Andrew Goodwin, Russell A. Higgins, Thomas Long, Wayne L. Chandler, Neil Harris, Huy P. Pham, (unknown), Karen Moser, John D. Olson, Kristi J. Smock, (unknown), Geoffrey D. Wool, Dong Chen	4
10	The Impact of COVID-19 Disease on Platelets and Coagulation breakdown → 2020 ·Pathobiology ·Geoffrey D. Wool, Jonathan Miller	320
11	Effective desensitization for a strong donor‐specific HLA antibody in a case of HLA‐mismatched allogeneic hematopoietic cell transplantation 2019 ·HLA ·Maneesh Kumar Misra, (unknown), Nicholas K. Brown, (unknown), (unknown), Michael R. Bishop, Geoffrey D. Wool, Andrew Artz, Susana R. Marino	3
12	Red blood cell exchange in patients with sickle cell disease—indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB 2018 ·Transfusion ·(unknown), (unknown), (unknown), Lisa Boggio, Kelley E. Capocelli, (unknown), Scott A. Koepsell, (unknown), Huy P. Pham, (unknown), John Weiss, Geoffrey D. Wool, Beverly W. Baron	31
13	Daratumumab and Red Cell Serologic Testing: A Single-Institution Experience 2017 ·American Journal of Clinical Pathology ·(unknown), Beverly W. Baron, (unknown), Geoffrey D. Wool	0
14	Bone Marrow Necrosis 2015 ·American Journal of Clinical Pathology ·Geoffrey D. Wool, Anne Deucher	18
15	HDL Apolipoprotein-Related Peptides in the Treatment of Atherosclerosis and other Inflammatory Disorders 2010 ·Current Pharmaceutical Design ·Godfrey S. Getz, Geoffrey D. Wool, Catherine A. Reardon	28
16	Biological Properties of Apolipoprotein A-I Mimetic Peptides 2010 ·Current Atherosclerosis Reports ·Godfrey S. Getz, Geoffrey D. Wool, Catherine A. Reardon	25
17	An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide 2009 ·Journal of Lipid Research ·Geoffrey D. Wool, Tomáš Vaisar, Catherine A. Reardon, Godfrey S. Getz	30
18	Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action 2009 ·Current Opinion in Lipidology ·Godfrey S. Getz, Geoffrey D. Wool, Catherine A. Reardon	28
19	Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties 2008 ·Journal of Lipid Research ·Geoffrey D. Wool, Catherine A. Reardon, Godfrey S. Getz	58
20	The Influence of Acute Phase Proteins on Murine Atherosclerosis 2007 ·Current Drug Targets ·Geoffrey D. Wool, Colin Reardon	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact